Connections between epigenetic gene silencing and human disease

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 618, Issue 1-2, 2007, Pages 163-174

  Moss, Timothy J ^a   Wallrath, Lori L ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Chromatin; DNA methylation; Epigenetic gene silencing; Histone methylation; Human disease

Indexed keywords

DNA; HETEROCHROMATIN PROTEIN 1; HISTONE H3;

ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE; DNA METHYLATION; ENZYME MODIFICATION; EPIGENETICS; GENE CONTROL; GENE INTERACTION; GENE LOSS; GENE MUTATION; GENE SILENCING; HETEROCHROMATIN; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN METHYLATION; PROTEIN STRUCTURE; VIRUS LATENCY;

ANIMALS; CHROMATIN; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; EPIGENESIS, GENETIC; GENE SILENCING; HISTONES; HUMANS; METHYLTRANSFERASES; MODELS, BIOLOGICAL; MODELS, GENETIC; MUTATION; REPRESSOR PROTEINS;

EID: 34247116336     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2006.05.038     Document Type: Article

References (144)

1. Ehrlich M., Buchanan K.L., Tsien F., Jiang G., Sun B., Uicker W., Weemaes C.M., Smeets D., Sperling K., Belohradsky B.H., Tommerup N., Misek D.E., Rouillard J.M., Kuick R., and Hanash S.M. DNA methyltransferase 3B mutations linked to the ICF syndrome cause dysregulation of lymphogenesis genes. Hum. Mol. Genet. 10 (2001) 2917-2931
2. Wade P.A. Methyl CpG-binding proteins and transcriptional repression. Bioessays 23 (2001) 1131-1137
3. Lund A.H., and van Lohuizen M. Epigenetics and cancer. Genes Dev. 18 (2004) 2315-2335
4. Boltze C., Schneider-Stock R., Quednow C., Hinze R., Mawrin C., Hribaschek A., Roessner A., and Hoang-Vu C. Silencing of the maspin gene by promoter hypermethylation in thyroid cancer. Int. J. Mol. Med. 12 (2003) 479-484
5. Futscher B.W., O'Meara M.M., Kim C.J., Rennels M.A., Lu D., Gruman L.M., Seftor R.E., Hendrix M.J., and Domann F.E. Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia 6 (2004) 380-389
6. Yatabe Y., Mitsudomi T., and Takahashi T. Maspin expression in normal lung and non-small-cell lung cancers: cellular property-associated expression under the control of promoter DNA methylation. Oncogene 23 (2004) 4041-4049
7. Delaval K., Wagschal A., and Feil R. Epigenetic deregulation of imprinting in congenital diseases of aberrant growth. Bioessays 28 (2006) 453-459
8. Lewis A., and Reik W. How imprinting centres work. Cytogenet. Genome Res. 113 (2006) 81-89
9. Biniszkiewicz D., Gribnau J., Ramsahoye B., Gaudet F., Eggan K., Humpherys D., Mastrangelo M.A., Jun Z., Walter J., and Jaenisch R. Dnmt1 overexpression causes genomic hypermethylation, loss of imprinting, and embryonic lethality. Mol. Cell Biol. 22 (2002) 2124-2135
10. Bell A.C., and Felsenfeld G. Methylation of a CTCF-dependent boundary controls imprinted expression of the Igf2 gene. Nature 405 (2000) 482-485
11. Schonherr N., Meyer E., Eggermann K., Ranke M.B., Wollmann H.A., and Eggermann T. (Epi)mutations in 11p15 significantly contribute to Silver-Russell syndrome: but are they generally involved in growth retardation?. Eur. J. Med. Genet. (2006)
12. Hassan A.H., Neely K.E., Vignali M., Reese J.C., and Workman J.L. Promoter targeting of chromatin-modifying complexes. Front Biosci. 6 (2001) D1054-D1064
13. Bickmore W.A., and van der Maarel S.M. Perturbations of chromatin structure in human genetic disease: recent advances. Hum. Mol. Genet. 12 Spec No 2 (2003) R207-R213
14. Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat. Rev. Genet. 3 (2002) 662-673
15. Moretti P., and Zoghbi H.Y. MeCP2 dysfunction in Rett syndrome and related disorders. Curr. Opin. Genet. Dev. 16 (2006) 276-281
16. Tudor M., Akbarian S., Chen R.Z., and Jaenisch R. Transcriptional profiling of a mouse model for Rett syndrome reveals subtle transcriptional changes in the brain. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 15536-15541
17. Chang Q., Khare G., Dani V., Nelson S., and Jaenisch R. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 49 (2006) 341-348
18. Sun Y.E., and Wu H. The ups and downs of BDNF in Rett syndrome. Neuron 49 (2006) 321-323
19. Young J.I., Hong E.P., Castle J.C., Crespo-Barreto J., Bowman A.B., Rose M.F., Kang D., Richman R., Johnson J.M., Berget S., and Zoghbi H.Y. Regulation of RNA splicing by the methylation-dependent transcriptional repressor methyl-CpG binding protein 2. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 17551-17558
20. Peterson C.L., and Laniel M.A. Histones and histone modifications. Curr. Biol. 14 (2004) R546-R551
21. Strahl B.D., and Allis C.D. The language of covalent histone modifications. Nature 403 (2000) 41-45
22. Fraga M.F., Ballestar E., Villar-Garea A., Boix-Chornet M., Espada J., Schotta G., Bonaldi T., Haydon C., Ropero S., Petrie K., Iyer N.G., Perez-Rosado A., Calvo E., Lopez J.A., Cano A., Calasanz M.J., Colomer D., Piris M.A., Ahn N., Imhof A., Caldas C., Jenuwein T., and Esteller M. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat. Genet. 37 (2005) 391-400
23. Kuzmichev A., Nishioka K., Erdjument-Bromage H., Tempst P., and Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 16 (2002) 2893-2905
24. Muller J., Hart C.M., Francis N.J., Vargas M.L., Sengupta A., Wild B., Miller E.L., O'Connor M.B., Kingston R.E., and Simon J.A. Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell 111 (2002) 197-208
25. Levine S.S., King I.F., and Kingston R.E. Division of labor in polycomb group repression. Trends Biochem. Sci. 29 (2004) 478-485
26. van der Vlag J., and Otte A.P. Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat. Genet. 23 (1999) 474-478
27. Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C., Morey L., Van Eynde A., Bernard D., Vanderwinden J.M., Bollen M., Esteller M., Di Croce L., de Launoit Y., and Fuks F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439 (2006) 871-874
28. Taghavi P., and van Lohuizen M. Developmental biology: two paths to silence merge. Nature 439 (2006) 794-795
29. Su I.H., Basavaraj A., Krutchinsky A.N., Hobert O., Ullrich A., Chait B.T., and Tarakhovsky A. Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement. Nat. Immunol. 4 (2003) 124-131
30. O'Carroll D., Erhardt S., Pagani M., Barton S.C., Surani M.A., and Jenuwein T. The polycomb-group gene Ezh2 is required for early mouse development. Mol. Cell Biol. 21 (2001) 4330-4336
31. Bracken A.P., Dietrich N., Pasini D., Hansen K.H., and Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Genes Dev. 20 (2006) 1123-1136
32. Bernstein B.E., Mikkelsen T.S., Xie X., Kamal M., Huebert D.J., Cuff J., Fry B., Meissner A., Wernig M., Plath K., Jaenisch R., Wagschal A., Feil R., Schreiber S.L., and Lander E.S. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125 (2006) 315-326
33. Buszczak M., and Spradling A.C. Searching chromatin for stem cell identity. Cell 125 (2006) 233-236
34. Sellers W.R., and Loda M. The EZH2 polycomb transcriptional repressor-a marker or mover of metastatic prostate cancer?. Cancer Cell 2 (2002) 349-350
35. Tang X., Milyavsky M., Shats I., Erez N., Goldfinger N., and Rotter V. Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23 (2004) 5759-5769
36. Tonini T., Bagella L., D'Andrilli G., Claudio P.P., and Giordano A. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A. Oncogene 23 (2004) 4930-4937
37. Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., and Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22 (2003) 5323-5335
38. Saramaki O.R., Tammela T.L., Martikainen P.M., Vessella R.L., and Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 45 (2006) 639-645
39. Varambally S., Dhanasekaran S.M., Zhou M., Barrette T.R., Kumar-Sinha C., Sanda M.G., Ghosh D., Pienta K.J., Sewalt R.G., Otte A.P., Rubin M.A., and Chinnaiyan A.M. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419 (2002) 624-629
40. Rhodes D.R., Sanda M.G., Otte A.P., Chinnaiyan A.M., and Rubin M.A. Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J. Natl. Cancer Inst. 95 (2003) 661-668
41. Kleer C.G., Cao Q., Varambally S., Shen R., Ota I., Tomlins S.A., Ghosh D., Sewalt R.G., Otte A.P., Hayes D.F., Sabel M.S., Livant D., Weiss S.J., Rubin M.A., and Chinnaiyan A.M. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 11606-11611
42. Ding L., Erdmann C., Chinnaiyan A.M., Merajver S.D., and Kleer C.G. Identification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissues. Cancer Res. 66 (2006) 4095-4099
43. Hobert O., Sures I., Ciossek T., Fuchs M., and Ullrich A. Isolation and developmental expression analysis of Enx-1, a novel mouse Polycomb group gene. Mech. Dev. 55 (1996) 171-184
44. Fukuyama T., Otsuka T., Shigematsu H., Uchida N., Arima F., Ohno Y., Iwasaki H., Fukuda T., and Niho Y. Proliferative involvement of ENX-1, a putative human polycomb group gene, in haematopoietic cells. Br. J. Haematol. 108 (2000) 842-847
45. Raaphorst F.M., Meijer C.J., Fieret E., Blokzijl T., Mommers E., Buerger H., Packeisen J., Sewalt R.A., Otte A.P., and van Diest P.J. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5 (2003) 481-488
46. Dukers D.F., van Galen J.C., Giroth C., Jansen P., Sewalt R.G., Otte A.P., Kluin-Nelemans H.C., Meijer C.J., and Raaphorst F.M. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am. J. Pathol. 164 (2004) 873-881
47. van Galen J.C., Dukers D.F., Giroth C., Sewalt R.G., Otte A.P., Meijer C.J., and Raaphorst F.M. Distinct expression patterns of polycomb oncoproteins and their binding partners during the germinal center reaction. Eur. J. Immunol. 34 (2004) 1870-1881
48. Sewalt R.G., Lachner M., Vargas M., Hamer K.M., den Blaauwen J.L., Hendrix T., Melcher M., Schweizer D., Jenuwein T., and Otte A.P. Selective interactions between vertebrate polycomb homologs and the SUV39H1 histone lysine methyltransferase suggest that histone H3-K9 methylation contributes to chromosomal targeting of Polycomb group proteins. Mol. Cell Biol. 22 (2002) 5539-5553
49. Rea S., Eisenhaber F., O'Carroll D., Strahl B.D., Sun Z.W., Schmid M., Opravil S., Mechtler K., Ponting C.P., Allis C.D., and Jenuwein T. Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406 (2000) 593-599
50. O'Carroll D., Scherthan H., Peters A.H., Opravil S., Haynes A.R., Laible G., Rea S., Schmid M., Lebersorger A., Jerratsch M., Sattler L., Mattei M.G., Denny P., Brown S.D., Schweizer D., and Jenuwein T. Isolation and characterization of Suv39h2, a second histone H3 methyltransferase gene that displays testis-specific expression. Mol. Cell Biol. 20 (2000) 9423-9433
51. Bannister A.J., Zegerman P., Partridge J.F., Miska E.A., Thomas J.O., Allshire R.C., and Kouzarides T. Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410 (2001) 120-124
52. Lachner M., O'Carroll D., Rea S., Mechtler K., and Jenuwein T. Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410 (2001) 116-120
53. Schotta G., Lachner M., Sarma K., Ebert A., Sengupta R., Reuter G., Reinberg D., and Jenuwein T. A silencing pathway to induce H3-K9 and H4-K20 trimethylation at constitutive heterochromatin. Genes Dev. 18 (2004) 1251-1262
54. Peters A.H., O'Carroll D., Scherthan H., Mechtler K., Sauer S., Schofer C., Weipoltshammer K., Pagani M., Lachner M., Kohlmaier A., Opravil S., Doyle M., Sibilia M., and Jenuwein T. Loss of the Suv39h histone methyltransferases impairs mammalian heterochromatin and genome stability. Cell 107 (2001) 323-337
55. Melcher M., Schmid M., Aagaard L., Selenko P., Laible G., and Jenuwein T. Structure-function analysis of SUV39H1 reveals a dominant role in heterochromatin organization, chromosome segregation, and mitotic progression. Mol. Cell Biol. 20 (2000) 3728-3741
56. Czvitkovich S., Sauer S., Peters A.H., Deiner E., Wolf A., Laible G., Opravil S., Beug H., and Jenuwein T. Over-expression of the SUV39H1 histone methyltransferase induces altered proliferation and differentiation in transgenic mice. Mech. Dev. 107 (2001) 141-153
57. Ait-Si-Ali S., Guasconi V., Fritsch L., Yahi H., Sekhri R., Naguibneva I., Robin P., Cabon F., Polesskaya A., and Harel-Bellan A. A Suv39h-dependent mechanism for silencing S-phase genes in differentiating but not in cycling cells. EMBO J. 23 (2004) 605-615
58. Nielsen S.J., Schneider R., Bauer U.M., Bannister A.J., Morrison A., O'Carroll D., Firestein R., Cleary M., Jenuwein T., Herrera R.E., and Kouzarides T. Rb targets histone H3 methylation and HP1 to promoters. Nature 412 (2001) 561-565
59. Braig M., Lee S., Loddenkemper C., Rudolph C., Peters A.H., Schlegelberger B., Stein H., Dorken B., Jenuwein T., and Schmitt C.A. Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436 (2005) 660-665
60. Palmero I., Pantoja C., and Serrano M. p19ARF links the tumour suppressor p53 to Ras. Nature 395 (1998) 125-126
61. Li Y., Kirschmann D.A., and Wallrath L.L. Does heterochromatin protein 1 always follow code?. Proc. Natl. Acad. Sci. U.S.A. 99 Suppl. 4 (2002) 16462-16469
62. Nielsen A.L., Oulad-Abdelghani M., Ortiz J.A., Remboutsika E., Chambon P., and Losson R. Heterochromatin formation in mammalian cells: interaction between histones and HP1 proteins. Mol. Cell 7 (2001) 729-739
63. Minc E., Allory Y., Worman H.J., Courvalin J.C., and Buendia B. Localization and phosphorylation of HP1 proteins during the cell cycle in mammalian cells. Chromosoma 108 (1999) 220-234
64. Cowieson N.P., Partridge J.F., Allshire R.C., and McLaughlin P.J. Dimerisation of a chromo shadow domain and distinctions from the chromodomain as revealed by structural analysis. Curr. Biol. 10 (2000) 517-525
65. Thiru A., Nietlispach D., Mott H.R., Okuwaki M., Lyon D., Nielsen P.R., Hirshberg M., Verreault A., Murzina N.V., and Laue E.D. Structural basis of HP1/PXVXL motif peptide interactions and HP1 localisation to heterochromatin. EMBO J. 23 (2004) 489-499
66. Danzer J.R., and Wallrath L.L. Mechanisms of HP1-mediated gene silencing in Drosophila. Development 131 (2004) 3571-3580
67. Wallrath L.L., and Elgin S.C. Position effect variegation in Drosophila is associated with an altered chromatin structure. Genes Dev. 9 (1995) 1263-1277
68. Bernard P., Maure J.F., Partridge J.F., Genier S., Javerzat J.P., and Allshire R.C. Requirement of heterochromatin for cohesion at centromeres. Science 294 (2001) 2539-2542
69. Ekwall K., Javerzat J.P., Lorentz A., Schmidt H., Cranston G., and Allshire R. The chromodomain protein Swi6: a key component at fission yeast centromeres. Science 269 (1995) 1429-1431
70. Nonaka N., Kitajima T., Yokobayashi S., Xiao G., Yamamoto M., Grewal S.I., and Watanabe Y. Recruitment of cohesin to heterochromatic regions by Swi6/HP1 in fission yeast. Nat. Cell Biol. 4 (2002) 89-93
71. Obuse C., Iwasaki O., Kiyomitsu T., Goshima G., Toyoda Y., and Yanagida M. A conserved Mis12 centromere complex is linked to heterochromatic HP1 and outer kinetochore protein Zwint-1. Nat. Cell Biol. 6 (2004) 1135-1141
72. Ainsztein A.M., Kandels-Lewis S.E., Mackay A.M., and Earnshaw W.C. INCENP centromere and spindle targeting: identification of essential conserved motifs and involvement of heterochromatin protein HP1. J. Cell Biol. 143 (1998) 1763-1774
73. Vagnarelli P.B., and Earnshaw W.C. INCENP loss from an inactive centromere correlates with the loss of sister chromatid cohesion. Chromosoma 110 (2001) 393-401
74. Fanti L., Giovinazzo G., Berloco M., and Pimpinelli S. The heterochromatin protein 1 prevents telomere fusions in Drosophila. Mol. Cell 2 (1998) 527-538
75. Cenci G., Ciapponi L., and Gatti M. The mechanism of telomere protection: a comparison between Drosophila and humans. Chromosoma 114 (2005) 135-145
76. Sharma G.G., Hwang K.K., Pandita R.K., Gupta A., Dhar S., Parenteau J., Agarwal M., Worman H.J., Wellinger R.J., and Pandita T.K. Human heterochromatin protein 1 isoforms HP1(Hsalpha) and HP1(Hsbeta) interfere with hTERT-telomere interactions and correlate with changes in cell growth and response to ionizing radiation. Mol. Cell Biol. 23 (2003) 8363-8376
77. Song K., Jung Y., Jung D., and Lee I. Human Ku70 interacts with heterochromatin protein 1alpha. J. Biol. Chem. 276 (2001) 8321-8327
78. Kirschmann D.A., Seftor E.A., Nieva D.R., Mariano E.A., and Hendrix M.J. Differentially expressed genes associated with the metastatic phenotype in breast cancer. Breast Cancer Res. Treat. 55 (1999) 127-136
79. Gehlsen K.R., Wagner Jr. H.N., and Hendrix M.J. Membrane invasion culture system (MICS). Med. Instrum. 18 (1984) 268-271
80. Khanna C., and Hunter K. Modeling metastasis in vivo. Carcinogenesis 26 (2005) 513-523
81. Kirschmann D.A., Lininger R.A., Gardner L.M., Seftor E.A., Odero V.A., Ainsztein A.M., Earnshaw W.C., Wallrath L.L., and Hendrix M.J. Down-regulation of HP1Hsalpha expression is associated with the metastatic phenotype in breast cancer. Cancer Res. 60 (2000) 3359-3363
82. Norwood L.E., Moss T.J., Margaryan N.V., Cook S.L., Wright L., Seftor E.A., Hendrix M.J., Kirschmann D.A., and Wallrath L.L. A requirement for dimerization of HP1Hsalpha in suppression of breast cancer invasion. J. Biol. Chem. 281 (2006) 18668-18676
83. Berger J.C., Vander Griend D.J., Robinson V.L., Hickson J.A., and Rinker-Schaeffer C.W. Metastasis suppressor genes: from gene identification to protein function and regulation. Cancer Biol. Ther. 4 (2005) 805-812
84. Steeg P.S., Ouatas T., Halverson D., Palmieri D., and Salerno M. Metastasis suppressor genes: basic biology and potential clinical use. Clin. Breast Cancer 4 (2003) 51-62
85. Wasenius V.M., Hemmer S., Kettunen E., Knuutila S., Franssila K., and Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin. Cancer Res. 9 (2003) 68-75
86. Pomeroy S.L., Tamayo P., Gaasenbeek M., Sturla L.M., Angelo M., McLaughlin M.E., Kim J.Y., Goumnerova L.C., Black P.M., Lau C., Allen J.C., Zagzag D., Olson J.M., Curran T., Wetmore C., Biegel J.A., Poggio T., Mukherjee S., Rifkin R., Califano A., Stolovitzky G., Louis D.N., Mesirov J.P., Lander E.S., and Golub T.R. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature 415 (2002) 436-442
87. Murphy J.C., Fischle W., Verdin E., and Sinclair J.H. Control of cytomegalovirus lytic gene expression by histone acetylation. EMBO J. 21 (2002) 1112-1120
88. Reeves M.B., Lehner P.J., Sissons J.G., and Sinclair J.H. An in vitro model for the regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin remodelling. J. Gen. Virol. 86 (2005) 2949-2954
89. Reeves M.B., MacAry P.A., Lehner P.J., Sissons J.G., and Sinclair J.H. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 4140-4145
90. Lim C., Lee D., Seo T., Choi C., and Choe J. Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus functionally interacts with heterochromatin protein 1. J. Biol. Chem. 278 (2003) 7397-7405
91. Rohr O., Lecestre D., Chasserot-Golaz S., Marban C., Avram D., Aunis D., Leid M., and Schaeffer E. Recruitment of Tat to heterochromatin protein HP1 via interaction with CTIP2 inhibits human immunodeficiency virus type 1 replication in microglial cells. J. Virol. 77 (2003) 5415-5427
92. Okada Y., Suzuki T., Sunden Y., Orba Y., Kose S., Imamoto N., Takahashi H., Tanaka S., Hall W.W., Nagashima K., and Sawa H. Dissociation of heterochromatin protein 1 from lamin B receptor induced by human polyomavirus agnoprotein: role in nuclear egress of viral particles. EMBO Rep. 6 (2005) 452-457
93. Tamaru H., and Selker E.U. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 414 (2001) 277-283
94. Jackson J.P., Lindroth A.M., Cao X., and Jacobsen S.E. Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase. Nature 416 (2002) 556-560
95. Malagnac F., Bartee L., and Bender J. An Arabidopsis SET domain protein required for maintenance but not establishment of DNA methylation. EMBO J. 21 (2002) 6842-6852
96. Johnson L., Cao X., and Jacobsen S. Interplay between two epigenetic marks. DNA methylation and histone H3 lysine 9 methylation. Curr. Biol. 12 (2002) 1360-1367
97. Tariq M., Saze H., Probst A.V., Lichota J., Habu Y., and Paszkowski J. Erasure of CpG methylation in Arabidopsis alters patterns of histone H3 methylation in heterochromatin. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 8823-8827
98. Soppe W.J., Jasencakova Z., Houben A., Kakutani T., Meister A., Huang M.S., Jacobsen S.E., Schubert I., and Fransz P.F. DNA methylation controls histone H3 lysine 9 methylation and heterochromatin assembly in Arabidopsis. EMBO J. 21 (2002) 6549-6559
99. Lehnertz B., Ueda Y., Derijck A.A., Braunschweig U., Perez-Burgos L., Kubicek S., Chen T., Li E., Jenuwein T., and Peters A.H. Suv39h-mediated histone H3 lysine 9 methylation directs DNA methylation to major satellite repeats at pericentric heterochromatin. Curr. Biol. 13 (2003) 1192-1200
100. Yan Q., Cho E., Lockett S., and Muegge K. Association of Lsh, a regulator of DNA methylation, with pericentromeric heterochromatin is dependent on intact heterochromatin. Mol. Cell Biol. 23 (2003) 8416-8428
101. Yan Q., Huang J., Fan T., Zhu H., and Muegge K. Lsh, a modulator of CpG methylation, is crucial for normal histone methylation. EMBO J. 22 (2003) 5154-5162
102. Freitag M., and Selker E.U. Controlling DNA methylation: many roads to one modification. Curr. Opin. Genet. Dev. 15 (2005) 191-199
103. Bird A.P., and Wolffe A.P. Methylation-induced repression-belts, braces, and chromatin. Cell 99 (1999) 451-454
104. Fuks F., Hurd P.J., Deplus R., and Kouzarides T. The DNA methyltransferases associate with HP1 and the SUV39H1 histone methyltransferase. Nucl. Acids Res. 31 (2003) 2305-2312
105. Fuks F., Hurd P.J., Wolf D., Nan X., Bird A.P., and Kouzarides T. The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J. Biol. Chem. 278 (2003) 4035-4040
106. Inche A.G., and La Thangue N.B. Chromatin control and cancer-drug discovery: realizing the promise. Drug Discov. Today 11 (2006) 97-109
107. Suzuki T., and Miyata N. Epigenetic control using natural products and synthetic molecules. Curr. Med. Chem. 13 (2006) 935-958
108. McGarvey K.M., Fahrner J.A., Greene E., Martens J., Jenuwein T., and Baylin S.B. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res. 66 (2006) 3541-3549
109. Trojer P., and Reinberg D. Histone lysine demethylases and their impact on epigenetics. Cell 125 (2006) 213-217
110. Li E., Bestor T.H., and Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell 69 (1992) 915-926
111. Lyko F., Ramsahoye B.H., Kashevsky H., Tudor M., Mastrangelo M.A., Orr-Weaver T.L., Jaenisch R., and Mammalian. (cytosine-5) methyltransferases cause genomic DNA methylation and lethality in Drosophila. Nat. Genet. 23 (1999) 363-366
112. Howell C.Y., Bestor T.H., Ding F., Latham K.E., Mertineit C., Trasler J.M., and Chaillet J.R. Genomic imprinting disrupted by a maternal effect mutation in the Dnmt1 gene. Cell 104 (2001) 829-838
113. el-Deiry W.S., Nelkin B.D., Celano P., Yen R.W., Falco J.P., Hamilton S.R., and Baylin S.B. High expression of the DNA methyltransferase gene characterizes human neoplastic cells and progression stages of colon cancer. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 3470-3474
114. Paz M.F., Wei S., Cigudosa J.C., Rodriguez-Perales S., Peinado M.A., Huang T.H., and Esteller M. Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum. Mol. Genet. 12 (2003) 2209-2219
115. Rhee I., Jair K.W., Yen R.W., Lengauer C., Herman J.G., Kinzler K.W., Vogelstein B., Baylin S.B., and Schuebel K.E. CpG methylation is maintained in human cancer cells lacking DNMT1. Nature 404 (2000) 1003-1007
116. Lee P.P., Fitzpatrick D.R., Beard C., Jessup H.K., Lehar S., Makar K.W., Perez-Melgosa M., Sweetser M.T., Schlissel M.S., Nguyen S., Cherry S.R., Tsai J.H., Tucker S.M., Weaver W.M., Kelso A., Jaenisch R., and Wilson C.B. A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. Immunity 15 (2001) 763-774
117. Gaudet F., Hodgson J.G., Eden A., Jackson-Grusby L., Dausman J., Gray J.W., Leonhardt H., and Jaenisch R. Induction of tumors in mice by genomic hypomethylation. Science 300 (2003) 489-492
118. Mizuno S., Chijiwa T., Okamura T., Akashi K., Fukumaki Y., Niho Y., and Sasaki H. Expression of DNA methyltransferases DNMT1, 3A, and 3B in normal hematopoiesis and in acute and chronic myelogenous leukemia. Blood 97 (2001) 1172-1179
119. Peng D.F., Kanai Y., Sawada M., Ushijima S., Hiraoka N., Kosuge T., and Hirohashi S. Increased DNA methyltransferase 1 (DNMT1) protein expression in precancerous conditions and ductal carcinomas of the pancreas. Cancer Sci. 96 (2005) 403-408
120. Tate P., Skarnes W., and Bird A. The methyl-CpG binding protein MeCP2 is essential for embryonic development in the mouse. Nat. Genet. 12 (1996) 205-208
121. Xu G.L., Bestor T.H., Bourc'his D., Hsieh C.L., Tommerup N., Bugge M., Hulten M., Qu X., Russo J.J., and Viegas-Pequignot E. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature 402 (1999) 187-191
122. Okano M., Bell D.W., Haber D.A., and Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99 (1999) 247-257
123. Jiang Y.L., Rigolet M., Bourc'his D., Nigon F., Bokesoy I., Fryns J.P., Hulten M., Jonveaux P., Maraschio P., Megarbane A., Moncla A., and Viegas-Pequignot E. DNMT3B mutations and DNA methylation defect define two types of ICF syndrome. Hum. Mutat. 25 (2005) 56-63
124. Beaulieu N., Morin S., Chute I.C., Robert M.F., Nguyen H., and MacLeod A.R. An essential role for DNA methyltransferase DNMT3B in cancer cell survival. J. Biol. Chem. 277 (2002) 28176-28181
125. Girault I., Tozlu S., Lidereau R., and Bieche I. Expression analysis of DNA methyltransferases 1, 3A, and 3B in sporadic breast carcinomas. Clin. Cancer Res. 9 (2003) 4415-4422
126. Saito Y., Kanai Y., Sakamoto M., Saito H., Ishii H., and Hirohashi S. Expression of mRNA for DNA methyltransferases and methyl-CpG-binding proteins and DNA methylation status on CpG islands and pericentromeric satellite regions during human hepatocarcinogenesis. Hepatology 33 (2001) 561-568
127. Saito Y., Kanai Y., Sakamoto M., Saito H., Ishii H., and Hirohashi S. Overexpression of a splice variant of DNA methyltransferase 3b, DNMT3b4, associated with DNA hypomethylation on pericentromeric satellite regions during human hepatocarcinogenesis. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 10060-10065
128. Lee S.J., Jeon H.S., Jang J.S., Park S.H., Lee G.Y., Lee B.H., Kim C.H., Kang Y.M., Lee W.K., Kam S., Park R.W., Kim I.S., Cho Y.L., Jung T.H., and Park J.Y. DNMT3B polymorphisms and risk of primary lung cancer. Carcinogenesis 26 (2005) 403-409
129. Shen H., Wang L., Spitz M.R., Hong W.K., Mao L., and Wei Q. A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. Cancer Res. 62 (2002) 4992-4995
130. Garcia-Cao M., O'Sullivan R., Peters A.H., Jenuwein T., and Blasco M.A. Epigenetic regulation of telomere length in mammalian cells by the Suv39h1 and Suv39h2 histone methyltransferases. Nat. Genet. 36 (2004) 94-99
131. Muller H.M., Fiegl H., Goebel G., Hubalek M.M., Widschwendter A., Muller-Holzner E., Marth C., and Widschwendter M. MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. Br. J. Cancer 89 (2003) 1934-1939
132. Amir R.E., Van den Veyver I.B., Wan M., Tran C.Q., Francke U., and Zoghbi H.Y. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat. Genet. 23 (1999) 185-188
133. Christodoulou J., Grimm A., Maher T., and Bennetts B. RettBASE: The IRSA MECP2 variation database-a new mutation database in evolution. Hum. Mutat. 21 (2003) 466-472
134. Merola E., Mattioli E., Minimo C., Zuo W., Rabitti C., Cicala M., Caviglia R., Pollice L., Gabbrielli A., Giordano A., and Claudio P.P. Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's esophagus. J. Cell Physiol. 207 (2006) 512-519
135. Arisan S., Buyuktuncer E.D., Palavan-Unsal N., Caskurlu T., Cakir O.O., and Ergenekon E. Increased expression of EZH2, a polycomb group protein, in bladder carcinoma. Urol. Int. 75 (2005) 252-257
136. Raman J.D., Mongan N.P., Tickoo S.K., Boorjian S.A., Scherr D.S., and Gudas L.J. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder. Clin. Cancer Res. 11 (2005) 8570-8576
137. Bachmann I.M., Halvorsen O.J., Collett K., Stefansson I.M., Straume O., Haukaas S.A., Salvesen H.B., Otte A.P., and Akslen L.A. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J. Clin. Oncol. 24 (2006) 268-273
138. Mimori K., Ogawa K., Okamoto M., Sudo T., Inoue H., and Mori M. Clinical significance of enhancer of zeste homolog 2 expression in colorectal cancer cases. Eur. J. Surg. Oncol. 31 (2005) 376-380
139. van Kemenade F.J., Raaphorst F.M., Blokzijl T., Fieret E., Hamer K.M., Satijn D.P., Otte A.P., and Meijer C.J. Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood 97 (2001) 3896-3901
140. Visser H.P., Gunster M.J., Kluin-Nelemans H.C., Manders E.M., Raaphorst F.M., Meijer C.J., Willemze R., and Otte A.P. The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br. J. Haematol. 112 (2001) 950-958
141. Croonquist P.A., and Van Ness B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24 (2005) 6269-6280
142. Sudo T., Utsunomiya T., Mimori K., Nagahara H., Ogawa K., Inoue H., Wakiyama S., Fujita H., Shirouzu K., and Mori M. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br. J. Cancer 92 (2005) 1754-1758
143. Zirn B., Hartmann O., Samans B., Krause M., Wittmann S., Mertens F., Graf N., Eilers M., and Gessler M. Expression profiling of Wilms tumors reveals new candidate genes for different clinical parameters. Int. J. Cancer 118 (2006) 1954-1962
144. Norwood L.E., Grade S.K., Cryderman D.E., Hines K.A., Furiasse N., Toro R., Li Y., Dhasarathy A., Kladde M.P., Hendrix M.J., Kirschmann D.A., and Wallrath L.L. Conserved properties of HP1(Hsalpha). Gene 336 (2004) 37-46